Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer

Modern Pathology

Volumn 24, Issue 5, 2011, Pages 720-728

  Schrevel, Marlies ^a   Gorter, Arko ^a   Kolkman Uljee, Sandra M ^a   Trimbos, J Baptist M Z ^a   Fleuren, Gert Jan ^a   Jordanova, Ekaterina S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

aneuploidy; cervical cancer; E5; E6; epidermal growth factor receptor; HPV

Indexed keywords

APOLIPOPROTEIN E5; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN E6;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CHROMOSOME 7; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ANEUPLOIDY; CHROMOSOMES, HUMAN, PAIR 7; COHORT STUDIES; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN PAPILLOMAVIRUS 16; HUMANS; IN SITU HYBRIDIZATION; MUTATION; NETHERLANDS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; RNA, VIRAL; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 79955592688     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.239     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872-880. (Pubitemid 41103599)
3. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; CD002225.
4. Kim GE, Kim YB, Cho NH, et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 2004;10:1366-1374. (Pubitemid 38365230)
5. Oh MJ, Choi JH, Kim IH, et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 2000;6: 4760-4763.
6. Mathur SP, Mathur RS, Young RC. Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer. Am J Reprod Immunol 2000;44: 222-230.
7. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-7251. (Pubitemid 46095395)
8. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biol Ther 2006;5: 340-342.
9. Dolgin E. FDA narrows drug label usage. Nature 2009;460:1069.
10. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11: 6414-6421. (Pubitemid 41338977)
11. Cohen MH, Williams GA, Sridhara R, et al. United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218. (Pubitemid 38365209)
12. Nicholas MK, Lukas RV, Jafri NF, et al. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006;12:7261-7270. (Pubitemid 46095397)
13. Rosell R, Taron M, Reguart N, et al. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006;12:7222-7231. (Pubitemid 46095393)
14. Del Campo JM, Prat A, Gil-Moreno A, et al. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 2008;110:S72-S76.
15. Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-586. (Pubitemid 29131967)
16. Noordhuis MG, Eijsink JJ, Ten Hoor KA, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)r-adiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-7397.
17. Arias-Pulido H, Joste N, Chavez A, et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer 2008;18:749-754. (Pubitemid 352020185)
18. Marzano R, Corrado G, Merola R, et al. Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression. Eur J Cancer 2004;40: 1624-1629. (Pubitemid 38757754)
19. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009;384: 324-334.
20. McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein. Virology 2009;384: 335-344.
21. Zyzak LL, MacDonald LM, Batova A, et al. Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes. Cell Growth Differ 1994;5:537-547. (Pubitemid 24251406)
22. Zhang B, Srirangam A, Potter DA, et al. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Onco-gene 2005;24:2585-2588. (Pubitemid 40593050)
23. Akerman GS, Tolleson WH, Brown KL, et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res 2001;61: 3837-3843. (Pubitemid 32695001)
24. Koopman LA, Szuhai K, van Eendenburg J, et al. Recurrent integration of human papillomaviruses 16, 45 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res 1999;59:5615-5624. (Pubitemid 29526482)
25. Haralambieva E, Kleiverda K, Mason DY, et al. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 2002;198:163-170. (Pubitemid 35243874)
26. Waye JS, England SB, Willard HF. Genomic organization of alpha satellite DNA on human chromosome 7: evidence for two distinct alphoid domains on a single chromosome. Mol Cell Biol 1987;7:349-356. (Pubitemid 17230417)
27. Corver WE, Ter Haar NT, Dreef EJ, et al. High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopula-tions in paraffin-embedded tissues. J Pathol 2005;206: 233-241. (Pubitemid 40754028)
28. de Boer MA, Jordanova ES, Kenter GG, et al. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 2007;13:132-138. (Pubitemid 46121861)
29. Kivi N, Greco D, Auvinen P, et al. Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Onco-gene 2008;27:2532-2541. (Pubitemid 351550881)
30. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034 (online article).
31. Hale RJ, Buckley CH, Gullick WJ, et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993;46:149-153. (Pubitemid 23076346)
32. Lee CM, Lee RJ, Hammond E, et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004;93: 209-214. (Pubitemid 38429572)
33. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12: 7232-7241. (Pubitemid 46095394)
34. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009;74:553-561.
35. Na II, Kang HJ, Cho SY, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007;43:520-526. (Pubitemid 46177596)
36. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96. (Pubitemid 32641351)
37. Manavi M, Hudelist G, Fink-Retter A, et al. Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol 2007;105:418-426. (Pubitemid 46590336)
38. Wilding J, Vousden KH, Soutter WP, et al. E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res 1996;56:5285-5292. (Pubitemid 26383049)
39. Hu G, Liu W, Mendelsohn J, et al. Expression of epidermal growth factor receptor and human papillo-mavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1271-1276. (Pubitemid 27371947)
40. Bheda A, Creek KE, Pirisi L. Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes. Oncogene 2008;27: 4315-4323. (Pubitemid 352009996)
41. Genther Williams SM, Disbrow GL, Schlegel R, et al. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papil-lomavirus oncogene. Cancer Res 2005;65:6534-6542. (Pubitemid 41060688)